- Collaboration with Xontogeny provides funding and key advisory support for early development -MALVERN, Pa. (BUSINESS WIRE) #Cardiovascular Shifa Biomedical Corporation (Shifa), a drug discovery company developing an oral small molecule PCSK9/low density lipoprotein-cholesterol receptor (LDLR) antagonist, P-21,.